that they’re not snake oil," said Dr. Gulfo, the former chief executive of MELA Sciences, who wrote a book about his company’s failed efforts to get its skin cancer detection device approved. (The agency eventually approved it for use in 2011.) Several drug company executives said the F. D. A. while not perfect, had sped up the approval process in recent years and had been responsive to requests to approve drugs based on interim measurements, particularly for   diseases that have no other treatments. The agency sets a   goal for approving standard drugs, and a   period for those that have qualified for expedited approval one recent study showed it decides on drugs more quickly than its counterparts in Europe and Canada. 